SynAct Pharma

SynAct Pharma is a biotech company aiming at resolving inflammation by leveraging melanocortin biology. Our lead asset AP1189 is in phase 2 development for the treatment of rheumatoid arthritis. AP1189 is an immunomodulatory small molecule delivered as a once-daily tablet. The mode of action is selective melanocortin receptor type 1 and 3 agonism, making it first-in-class. Activation of these receptors results in reduced secretion of proinflammatory cytokines by neutrophils and in conversion of macrophages towards clearing away cellular debris in hyper-inflamed tissue – two effects that together induce resolution of inflammation. The Phase 2a BEGIN study in patients with rheumatoid arthritis reported very promising efficacy and safety results in November 2021 - next step is to open an IND with FDA to get advice on further development. Due to the known Mode of Action, then AP1189 was also tested in COVID-19 positive patients with respiratory insufficiency. Results were reported in July 2021, demonstrating 4 days earlier respiratory recovery, 3 days earlier hospital discharge and more than 50% reduced risk of progressing to needing mechanical ventilation.